Evidence map›Paper›PMID 39112949›Full record

SynthesisBMC pediatrics2024

Opioid and benzodiazepine requirements in critically ill post-surgical children with down syndrome: a systematic review and meta-analysis.

Shaimaa Alsulami, Ashjan Alghanem, Renad AlShuraim, Khalid Al Sulaiman, Omer Ahmed Abdelwahab, Sarah Aljohani, Hadeel Alkofide, Mashael AlFaifi, Tarek Hazwani, Ohoud Aljuhani

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in BMC pediatrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shaimaa AlsulamiDepartment of Pharmacy Practice, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
Ashjan AlghanemPharmaceutical Care Division, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Renad AlShuraimPharmaceutical Care Department, King Saud Medical City, Riyadh, Saudi Arabia.
Khalid Al SulaimanPharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia. alsulaimankh@hotmail.com.
Omer Ahmed AbdelwahabFaculty of Medicine, Al-Azhar University, Cairo, Egypt.
Sarah AljohaniPharmaceutical Care Services, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia.
Hadeel AlkofideDepartment of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Mashael AlFaifiPharmaceutical Care Department, King Saud Medical City, Riyadh, Saudi Arabia.
Tarek HazwaniKing Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
Ohoud AljuhaniDepartment of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDown syndrome (DS), or Trisomy 21, is defined by the existence of an additional chromosome 21. Various physiological considerations in DS patients might lead to challenges in adequate pain management and sedation after surgery. The aim of this systematic review and meta-analysis is to evaluate the variations of the requirement needed for pain management and sedation in patients with DS who have undergone surgery compared to patients without DS.

methodsA systematic review and meta-analysis of studies were conducted, focusing on critically ill patients with DS who were admitted to Intensive care units (ICUs) post-surgery and received opioids and/or benzodiazepines. Searches were conducted in four databases from their inception to November 18, 2023 (Pubmed, Scopus, Cochrane Library, and Web of Science). The primary outcome measured was the dosage of Oral Morphine Equivalent (OME) administered in the days following surgery. Fixed-effect models were used, an approach advisable when only a limited number of studies are available.

resultsOut of the 992 studies initially screened, the systematic review included ten studies, encompassing 730 patients, while the meta-analysis consisted of seven studies, encompassing 533 patients. Of the seven studies included in the analysis, 298 patients were identified to have DS, and 235 patients served as controls. Patients with DS showed a slight increase in OME needs on the first day, but this increase was not statistically significant (mean difference [MD] = 0.09; 95% Confidence Interval [CI]: [-0.02, 0.20]; P = 0.11). There was also no significant difference in the requirement for Midazolam on the first day among DS patients (MD = 0.01; CI [-0.16, 0.19]; P = 0.88). In addition, the duration of mechanical ventilation was not statistically significant in patients with DS compared with the control group (MD = -1.46 hours; 95% CI [-9.74, 6.82]; P = 0.73).

conclusionPatients with Down syndrome did not require more sedation or analgesia in the first three days after surgery than patients without Down syndrome. Additionally, the two groups showed no significant difference in the duration of mechanical ventilation.

Indexed as

Analgesics, OpioidBenzodiazepinesCritical IllnessDown SyndromePostoperative PainChildHumansHypnotics and SedativesPain ManagementAnalgesics, OpioidBenzodiazepinesHypnotics and SedativesAnalgesiaCritical careDown syndromePost surgerySedationTrisomy 21

Identifiers

PMID39112949
PMCPMC11304697

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.